Skip to main content
Subscribe
Register
Sign in
Membership
Events
Knowledge Center
About
Subscribe
Register
Sign in
Valeant Pharmaceuticals
Latest Articles
The Morning Brief: Cooperman on Netflix, First Data and Fees
Stephen Taub
September 1, 2016
Daily Agenda: Clinton Secures Nomination. What’s Next for the Markets?
Andrew Barber
June 7, 2016
The Morning Brief: Managed Futures Funds Weather Turbulence in April
Stephen Taub
May 19, 2016
The Morning Brief: At SALT— Heat, Light and a Few Ideas
Stephen Taub
May 12, 2016
Premium
Valeant’s Winners and Losers
Stephen Taub
March 16, 2016
The Morning Brief: Alcoa Trades Expanded Board for Elliott’s Support
Stephen Taub
February 2, 2016
Aggressive Pharma Ads Yield Results — and Complaints
Khadijah M Silver
December 4, 2015
Drug Wars: The Battle to Put a Lid on Rising Prices
Khadijah M Silver
November 25, 2015
The Morning Brief: Marcato’s McGuire Exits NCR Board
Stephen Taub
November 13, 2015
The Morning Brief: Valeant Slips as Investors Bail
Stephen Taub
November 12, 2015
The Morning Brief: Pershing Square Plans Conference Call on Valeant
Stephen Taub
October 28, 2015
Daily Agenda: The Week Ahead, October 26 – 31, 2015
Andrew Barber
October 24, 2015
Hedge Fund Manager Kyle Bass Declares War on Drug Prices
Jess Delaney
October 22, 2015
Premium
Tourbillon Thrives on a Heady Mix of PR and Performance
Stephen Taub
June 9, 2015
Premium
Tiger Bloc’s Biggest Holdings: Actavis, CDK and JD.com
Stephen Taub
June 4, 2015
Premium
Jana Partners Absorbs Another Monthly Loss
Stephen Taub
May 4, 2015
Premium
Viking Global Breaks with Tiger Cubs and Bets on Health Care
Stephen Taub
April 30, 2015
Premium
Activists Turn Out a Strong First Quarter
Stephen Taub
April 21, 2015
More Articles